Publication | Closed Access

IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

Progression-free SurvivalAdvanced Non-squamous NsclcMedicinePharmacologyImmune Checkpoint InhibitorPharmacotherapySafety AnalysisAnti-cancer AgentCancer TreatmentOncologyLung Cancer